Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling
Open Access
- 6 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Allergy, Asthma & Clinical Immunology
- Vol. 17 (1), 1-10
- https://doi.org/10.1186/s13223-021-00566-x
Abstract
Subcutaneous immunotherapy (SCIT) is an effective treatment for allergic rhinoconjunctivitis. However, adverse events, including life-threatening systemic reactions, may occur. The purpose of this project is to identify risk factors for systemic reactions to SCIT and to provide practice-based solutions using a quality improvement (QI) framework. A QI initiative was performed in a hospital-based, Canadian Allergy clinic administering SCIT in a 12-month period. A total of 4242 injections of SCIT were performed over a period of 12 months. Of these, 10 injections resulted in a systemic reaction requiring epinephrine administration (i.e., an incidence of 1 in 424 injections, or 0.24%). Eight patients had at least one documented risk factor for a systemic reaction, and six had multiple risk factors. Major risk factors included seasonal exacerbation of allergic rhinitis, uncontrolled asthma, and an error in route of administration. All reactions occurred with the highest allergen extract concentration. This QI initiative highlights the need for improved patient and health care practitioner education and pre-administration screening. We suggest several considerations for SCIT administration: provide patients with written information on safety; screen patients before injections, including a review of treatment plan adherence and asthma control; adjust dosing to slow down buildup of the most concentrated immunotherapy extract, particularly in high risk patients; and apply additional safety measures in patients with multiple risk factors.Keywords
This publication has 27 references indexed in Scilit:
- Allergen immunotherapy: A practice parameter third updateJournal of Allergy and Clinical Immunology, 2011
- An update on the safety of specific immunotherapyCurrent Opinion in Allergy and Clinical Immunology, 2008
- Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapyAnnals of Allergy, Asthma & Immunology, 2008
- Allergen immunotherapy safety: Characterizing systemic reactions and identifying risk factorsAllergy and Asthma Proceedings, 2008
- Evaluation of near-fatal reactions to allergen immunotherapy injectionsJournal of Allergy and Clinical Immunology, 2006
- Insect sting allergy and venom immunotherapy: A model and a mysteryJournal of Allergy and Clinical Immunology, 2005
- Incorrect allergy injections: Allergists' experiences and recommendations for preventionJournal of Allergy and Clinical Immunology, 2004
- Immunotherapy safety: a prospective multi‐centric monitoring study of biologically standardized therapeutic vaccines for allergic diseasesClinical & Experimental Allergy, 2004
- Rapid Hymenoptera venom immunotherapy: comparative safety of three protocolsClinical & Experimental Allergy, 1993
- Late systemic-allergic reactions to inhalant allergen immunotherapyJournal of Allergy and Clinical Immunology, 1988